Molecular probing of the HPV-16 E6 protein alpha helix binding groove with small molecule inhibitors

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Rietz, Anne ^a   Petrov, Dino P ^b   Bartolowits, Matthew ^b   DeSmet, Marsha ^a   Davisson, V Jo ^b   Androphy, Elliot J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DISUBSTITUTED BENZOPYRANONE; ALANINE; ARGININE; BENZOPYRAN DERIVATIVE; CELL PROTEIN; MALTOSE; MBP PROTEIN; PROTEIN E6; PROTEIN P53; UNCLASSIFIED DRUG; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; MOLECULAR PROBE; ONCOPROTEIN; PROTEIN BINDING; REPRESSOR PROTEIN;

ALPHA HELIX BINDING GROOVE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DISSOCIATION CONSTANT; HUMAN PAPILLOMAVIRUS TYPE 16; HYDROGEN BOND; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR PROBE; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; STRUCTURE ACTIVITY RELATION; THERMOSTABILITY; ANTAGONISTS AND INHIBITORS; CHEMICAL PHENOMENA; CHEMISTRY; METABOLISM; PHARMACOLOGY; PROTEIN SECONDARY STRUCTURE;

BENZOPYRANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR PROBES; ONCOGENE PROTEINS, VIRAL; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; REPRESSOR PROTEINS;

EID: 84979072348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0149845     Document Type: Article

References (50)

1. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011; 29(32):4294-301. Epub 2011/10/05. JCO.2011.36.4596 [pii] doi: 10.1200/JCO.2011.36.4596 PMID: 21969503; PubMed Central PMCID: PMC3221528.
2. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res. 2009; 15(22):6758-62. Epub 2009/10/29. 1078-0432.CCR-09-0784 [pii] doi: 10.1158/1078-0432.CCR-09-0784 PMID: 19861444.
3. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003; 348 (6):518-27. PMID: 12571259.
4. zur Hausen H. Papillomaviruses in human cancers. Proc Assoc Am Physicians. 1999; 111(6):581-7. PMID: 10591087
5. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010; 10(8):550-60. doi: 10.1038/nrc2886 PMID: 20592731
6. Vande Pol SB, Klingelhutz AJ. Papillomavirus E6 oncoproteins. Virology. 2013; 445(1-2):115-37. doi: 10.1016/j.virol.2013.04.026 PMID: 23711382; PubMed Central PMCID: PMC3783570.
7. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993; 75:495-505. PMID: 8221889
8. Scheffner M, Huibregtse JM, Howley PM. Identification of a human ubiquitin-conjugating enzyme that mediates the E6-AP-dependent ubiquitination of p53. Proc Natl Acad Sci USA. 1994; 91(19):8797-801. PMID: 8090726
9. Filippova M, Parkhurst L, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. J Biol Chem. 2004; 279 (24):25729-44. PMID: 15073179.
10. Horner SM, DeFilippis RA, Manuelidis L, DiMaio D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol. 2004; 78(8):4063-73. PMID: 15047823.
11. Hu Y, Ye F, Lu W, Hong D, Wan X, Xie X. HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells. Cancer Invest. 2009; 27(3):298-306. Epub 2009/02/06. 908491031 [pii] doi: 10.1080/07357900802350798 PMID: 19194825.
12. Filippova M, Song H, Connolly JL, Dermody TS, Duerksen-Hughes PJ. The human papillomavirus 16 E6 protein binds to tumor necrosis factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem. 2002; 277(24):21730-9. PMID: 11934887.
13. Garnett TO, Filippova M, Duerksen-Hughes PJ. Accelerated degradation of FADD and procaspase 8 in cells expressing human papilloma virus 16 E6 impairs TRAIL-mediated apoptosis. Cell Death Differ. 2006; 13(11):1915-26. PMID: 16528386.
14. Liu Y, Liu Z, Androphy E, Chen J, Baleja JD. Design and Characterization of Helical Peptides that Inhibit the E6 Protein of Papillomavirus. Biochemistry. 2004; 43(23):7421-31. doi: 10.1021/bi049552a PMID: 15182185
15. Be X, Hong Y, Wei J, Androphy EJ, Chen JJ, Baleja JD. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP. Biochemistry. 2001; 40(5):1293-9. PMID: 11170455.
16. Ramirez J, Poirson J, Foltz C, Chebaro Y, Schrapp M, Meyer A, et al. Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand. Angew Chem Int Ed Engl. 2015; 54(27):7958-62. doi: 10.1002/anie.201502646 PMID: 26014966; PubMed Central PMCID: PMC4512291.
17. Karlsson OA, Ramirez J, Oberg D, Malmqvist T, Engstrom A, Friberg M, et al. Design of a PDZbody, a bivalent binder of the E6 protein from human papillomavirus. Sci Rep. 2015; 5:9382. doi: 10.1038/srep09382 PMID: 25797137; PubMed Central PMCID: PMCPMC4369733.
18. Zanier K, Stutz C, Kintscher S, Reinz E, Sehr P, Bulkescher J, et al. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6. PloS one. 2014; 9(11):e112514. doi: 10.1371/journal.pone.0112514 PMID: 25383876; PubMed Central PMCID: PMC4226571.
19. Stutz C, Reinz E, Honegger A, Bulkescher J, Schweizer J, Zanier K, et al. Intracellular Analysis of the Interaction between the Human Papillomavirus Type 16 E6 Oncoprotein and Inhibitory Peptides. PloS one. 2015; 10(7):e0132339. doi: 10.1371/journal.pone.0132339 PMID: 26151636; PubMed Central PMCID: PMC4495056.
20. Xie X, Piao L, Bullock BN, Smith A, Su T, Zhang M, et al. Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma. Oncogene. 2014; 33(8):1037-46. doi: 10.1038/onc.2013.25 PMID: 23474763; PubMed Central PMCID: PMC3912227.
21. Manzo-Merino J, Thomas M, Fuentes-Gonzalez AM, Lizano M, Banks L. HPV E6 oncoprotein as a potential therapeutic target in HPV related cancers. Expert Opin Ther Targets. 2013; 17(11):1357-68. doi: 10.1517/14728222.2013.832204 PMID: 24094136
22. Zanier K, Charbonnier S, Sidi AOMhO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al. Structural Basis for Hijacking of Cellular LxxLL Motifs by Papillomavirus E6 Oncoproteins. Science. 2013; 339(6120):694-8. doi: 10.1126/science.1229934 PMID: 23393263
23. Kumar S, Jena L, Galande S, Daf S, Mohod K, Varma AK. Elucidating Molecular Interactions of Natural Inhibitors with HPV-16 E6 Oncoprotein through Docking Analysis. Genomics & informatics. 2014; 12 (2):64-70. doi: 10.5808/GI.2014.12.2.64 PMID: 25031569; PubMed Central PMCID: PMC4099350.
24. Kumar S, Jena L, Mohod K, Daf S, Varma AK. Virtual Screening for Potential Inhibitors of High-Risk Human Papillomavirus 16 E6 Protein. Interdisciplinary sciences, computational life sciences. 2015; 7 (2):136-42. doi: 10.1007/s12539-015-0008-z PMID: 26199214.
25. Cherry JJ, Rietz A, Malinkevich A, Liu Y, Xie M, Bartolowits M, et al. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function. PloS one. 2013; 8(12): e84506. doi: 10.1371/journal.pone.0084506 PMID: 24376816; PubMed Central PMCID: PMCPMC3871595.
26. Yuan CH, Filippova M, Tungteakkhun SS, Duerksen-Hughes PJ, Krstenansky JL. Small molecule inhibitors of the HPV16-E6 interaction with caspase 8. Bioorganic & medicinal chemistry letters. 2012; 22(5):2125-9. doi: 10.1016/j.bmcl.2011.12.145 PMID: 22300659; PubMed Central PMCID: PMC3288179.
27. Malecka KA, Fera D, Schultz DC, Hodawadekar S, Reichman M, Donover PS, et al. Identification and characterization of small molecule human papillomavirus E6 inhibitors. ACS Chem Biol. 2014; 9 (7):1603-12. doi: 10.1021/cb500229d PMID: 24854633; PubMed Central PMCID: PMC4145632.
28. Nomine Y, Ristriani T, Laurent C, Lefevre JF, Weiss E, Trave G. A strategy for optimizing the monodispersity of fusion proteins: application to purification of recombinant HPV E6 oncoprotein. Protein engineering. 2001; 14(4):297-305. PMID: 11391022.
29. Zanier K, ould M'hamed ould Sidi A, Boulade-Ladame C, Rybin V, Chappelle A, Atkinson A, et al. Solution Structure Analysis of the HPV16 E6 Oncoprotein Reveals a Self-Association Mechanism Required for E6-Mediated Degradation of p53. Structure. 2012; 20(4):604-17. doi: 10.1016/j.str.2012.02.001 PMID: 22483108
30. Sekaric P, Cherry JJ, Androphy EJ. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT. Journal of virology. 2008; 82(1):71-6. doi: 10.1128/JVI.01776-07 PMID: 17942561; PubMed Central PMCID: PMC2224393.
31. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol. 1999; 73(8):6209-19. PMID: 10400710; PubMed Central PMCID: PMC112697.
32. Liu Y, Chen JJ, Gao QS, Dalal S, Hong YH, Mansur CP, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol. 1999; 73(9):7297-307. PMID: 10438818
33. Pantoliano MW, Petrella EC, Kwasnoski JD, Lobanov VS, Myslik J, Graf E, et al. High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery. J Biomol Screen. 2001; 6(6):429-40. doi: 10.1177/108705710100600609 PMID: 11788061
34. Novokhatny V, Ingham K. Thermodynamics of maltose binding protein unfolding. Protein science: a publication of the Protein Society. 1997; 6(1):141-6. doi: 10.1002/pro.5560060116 PMID: 9007986; PubMed Central PMCID: PMC2143499.
35. Imai Y, Tsunokawa Y, Sugimura T, Terada M. Purification and DNA-binding properties of human papillomavirus type 16 E6 protein expressed in Escherichia coli. Biochemical and biophysical research communications. 1989; 164(3):1402-10. PMID: 2556128.
36. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol. 1994; 68(7):4262-73. PMID: 8207801; PubMed Central PMCID: PMC236349.
37. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010; 53(7):2719-40. doi: 10.1021/jm901137j PMID: 20131845.
38. Pohjala L, Tammela P. Aggregating Behavior of Phenolic Compounds - A Source of False Bioassay Results? Molecules. 2012; 17(9):10774-90. doi: 10.3390/molecules170910774 PMID: 22960870
39. Zanier K, Charbonnier S, Sidi AO, McEwen AG, Ferrario MG, Poussin-Courmontagne P, et al. Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science. 2013; 339 (6120):694-8. doi: 10.1126/science.1229934 PMID: 23393263; PubMed Central PMCID: PMC3899395.
40. Gagnon D, Archambault J. A high-throughput cellular assay to quantify the p53-degradation activity of E6 from different human papillomavirus types. Methods Mol Biol. 2015; 1249:111-20. doi: 10.1007/978-1-4939-2013-6-8 PMID: 25348301.
41. Shamanin VA, Sekaric P, Androphy EJ. hAda3 degradation by papillomavirus type 16 E6 correlates with abrogation of the p14ARF-p53 pathway and efficient immortalization of human mammary epithelial cells. Journal of virology. 2008; 82(8):3912-20. doi: 10.1128/JVI.02466-07 PMID: 18256148; PubMed Central PMCID: PMC2293003.
42. Guo Y, Meng X, Wang Q, Wang Y, Shang H. The ING4 Binding with p53 and Induced p53 Acetylation were Attenuated by Human Papillomavirus 16 E6. PloS one. 2013; 8(8):e71453. doi: 10.1371/journal.pone.0071453 PMID: 23967213; PubMed Central PMCID: PMC3742747.
43. Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014; 21(9):1102-14. doi: 10.1016/j.chembiol.2014.09.001 PMID: 25237857; PubMed Central PMCID: PMC4179228.
44. Baleja JD, Cherry JJ, Liu Z, Gao H, Nicklaus MC, Voigt JH, et al. Identification of inhibitors to papillomavirus type 16 E6 protein based on three-dimensional structures of interacting proteins. Antiviral research. 2006; 72(1):49-59. doi: 10.1016/j.antiviral.2006.03.014 PMID: 16690141; PubMed Central PMCID: PMC2776632.
45. Huang Y, Wolf S, Beck B, Kohler LM, Khoury K, Popowicz GM, et al. Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities. ACS Chem Biol. 2014; 9(3):802-11. doi: 10.1021/cb400728e PMID: 24405416; PubMed Central PMCID: PMCPMC3985958.
46. Sun D, Li Z, Rew Y, Gribble M, Bartberger MD, Beck HP, et al. Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development. J Med Chem. 2014; 57 (4):1454-72. doi: 10.1021/jm401753e PMID: 24456472.
47. Sherman W, Beard HS, Farid R. Use of an induced fit receptor structure in virtual screening. Chem Biol Drug Des. 2006; 67(1):83-4. doi: 10.1111/j.1747-0285.2005.00327.x PMID: 16492153.
48. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem. 2006; 49(2):534-53. doi: 10.1021/jm050540c PMID: 16420040.
49. Bowers KJ, Chow E, Xu H, Dror RO, Eastwood MP, Gregersen BA, et al., editors. Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters. Proceedings of the ACM/IEEE SC 2006 Conference; 2006 2006/11//.
50. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996; 14(1):33-8, 27-8. PMID: 8744570.